26 LANDSDOWNE STREET, CAMBRIDGE, MA
Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
Beam Therapeutics Inc. Elects Class III Directors at Annual Meeting
Reports First Quarter 2026 Financial Results and Recent Business Updates
Annual Report to Security Holders
Termination of License Agreement with Bio Palette Co., Ltd.
Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
Material Contracts
Director Resignation - Carole Ho Steps Down from Beam Therapeutics Board
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Free Writing Prospectus